# EDGAR Filing Document

**Accession Number:** 0001904501
**File Stem:** 0001062993-25-012175
**Filing Date:** 2025-6
**Character Count:** 6032
**Document Hash:** ff1d16faf9e12c0ee63fb801362b5035
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-012175.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001062993-25-012175

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250626

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentek Ltd.
- **CENTRAL INDEX KEY:** 0001904501
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41310
- **FILM NUMBER:** 251081879

**BUSINESS ADDRESS:**
- **STREET 1:** 24 CORPORATE CT
- **CITY:** GUELPH
- **STATE:** A6
- **ZIP:** N1G 5G5
- **BUSINESS PHONE:** (844) 730-9822

**MAIL ADDRESS:**
- **STREET 1:** 24 CORPORATE CT
- **CITY:** GUELPH
- **STATE:** A6
- **ZIP:** N1G 5G5

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of <u>**June 2025**</u>

Commission File Number: **<u>001-41310</u>**

**<u>ZENTEK LTD.</u>**

(Registrant)

**24 Corporate Court**

<u>**Guelph, Ontario N1G 5G5 Canada**</u>

(Address of Principal Executive Offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

<u>**SIGNATURES**</u><br>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZENTEK LTD.** | **ZENTEK LTD.** |
|  | (Registrant) | (Registrant) |
| Date: June 26, 2025 | By | /s/ Wendy Ford |
|  |  | Wendy Ford |
|  |  | Chief Financial Officer |

---

------

<u>**EXHIBIT INDEX**</u>

---

| | |
|:---|:---|
| <u>**Exhibit**</u> | <u>**Description of Exhibit**</u> |
| [99.1](exhibit99-1.htm) | [Press Release dated June 26, 2025 - Zentek Provides Regulatory Update on ZenGUARD™ Enhanced Air Filters](exhibit99-1.htm) |

---

------

## Exhibit 99.1

------

![](exhibit99-1x001.jpg)

**Zentek Provides Regulatory Update on** 

**ZenGUARD<sup>™</sup>** **Enhanced Air Filters**

**Guelph, ON - June 26, 2025 - Zentek Ltd.** ("**Zentek**" or the "**Company**") (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property technology development and commercialization company, reports that it has received a letter from Health Canada noting that Health Canada is considering the classification of *Z*enGUARD™ Enhanced Air Filters and inviting Zentek to submit additional information regarding appropriate regulatory classification.

*Z*enGUARD™ Enhanced Air Filters were being assessed by the Health Canada Pest Management Regulatory Agency ("**PMRA**") for registration under the Pest Control Products Act. On October 31, 2024, the Company announced that it had withdrawn its submission to PMRA for its *Z*enGUARD™ Enhanced Air Filters to pursue a more appropriate pathway to commercialization in Canada. Accordingly, on November 27, 2024, the Company announced its intention to market *Z*enGUARD™ Enhanced Air Filters as a Class I medical device under its existing MDEL, similar to its surgical masks.

**About Zentek Ltd.** 

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

**For further information:** 

<u>investorrelations@zentek.com</u>

Ryan Shacklock

<u>Email:</u> <u>rshacklock@zentek.com</u>

<u>306-270-9610</u>

------

To find out more about Zentek, please visit our website at <u>www.Zentek.com</u>. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at <u>http://www.sedarplus.ca/</u>.

**Forward-Looking Statements** 

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

------